Core Points - The company has announced a fixed cash dividend distribution plan for the fiscal year 2024, with a total cash dividend amounting to 75,211,298.80 RMB [1][5][6] - The dividend distribution will be 1.00 RMB per 10 shares (including tax), with the record date set for June 5, 2025, and the ex-dividend date on June 6, 2025 [2][3][4] - The total share capital after excluding repurchased shares is 752,112,988 shares, which serves as the basis for the dividend distribution [1][4][6] Dividend Distribution Details - The cash dividend per share, calculated based on the total share capital (including repurchased shares), is 0.0974701 RMB per share [2][6] - The company will not issue bonus shares or increase capital through the capital reserve this year, with any undistributed profits carried forward to the next year [2][3] - The company will not deduct individual income tax for certain shareholders at this time, with tax obligations determined based on holding periods when shares are sold [3][4] Shareholder Information - The dividend distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [3][4] - Shares held in the company's repurchase account will not participate in this profit distribution [4][6] - The company has completed the cancellation of 60,000 restricted shares, adjusting the total share capital accordingly [2][3]

证券代码：002688 证券简称：金河生物 公告编号：2025-044 金河生物科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 特别提示： | 分红年度：2024 年年度权益分派 | | | | | 分配方案：分配比例固定 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股权登记日：2025 6 | 年 | 月 | 5 | 日 | 除权除息日为：2025 年 6 | 月 | 6 | 日 | | 除权前总股本：771,634,398 | | | | 股 | 回购专户上已回购的股份数量：19,521,410 | | | 股 | | 每 10 股派息（含税）：1 | | | 元 | | 现金分红总额：75,211,298.80 元 | | | | | 除权后总股本：771,634,398 | | | | 股 | | | | | 按 A 股除权前总股本（含回购股份及其他不参与分红的股份）计算的每 10 股派息 （含税）：0 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-043 金河生物科技股份有限公司 2024年度股东大会决议的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 特别提示： 1、本次股东大会无否决提案的情形。 5、会议召集人：公司董事会 2、本次股东大会没有涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 金河生物科技股份有限公司（以下简称"公司"）2024 年度股东大会通知 于 2025 年 4 月 26 日在《上海证券报》、《证券时报》、《证券日报》、《中国 证券报》及巨潮资讯网（www.cninfo.com.cn）以公告方式发出。 1、召开时间 （1）现场会议召开时间：2025 年 5 月 23 日下午 14:30 （2）网络投票时间：2025 年 5 月 23 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 23 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证 券交易所互联网投票系统投票的具体时间为：2025 年 5 月 23 ...

華聯律師事務所 年度股东大会的法律意见书 致：金河生物科技股份有限公司 根据中国证监会发布的《上市公司股东大会规则》（下称《" 股东大会规则》"） 的有关规定，北京市华联律师事务所（下称"本所"）接受金河生物科技股份有 限公司（下称"公司"）的委托，指派赫志律师、郝丽霞律师出席公司 2024 年 年度股东大会（下称"本次股东大会"），并就本次股东大会的召集和召开程序、 召集人资格、出席会议人员资格、会议的表决程序及表决结果等事宜发表法律意 见。 本所及经办律师依据《中华人民共和国证券法》（以下简称《证券法》）《律 师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则(试 行)》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了 法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法 律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存 在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 一、本次股东大会的召集和召开程序 本次股东大会由公司董事会根据 2025 年 4 月 25 日召开的第六届董事会第 二十五次会议召集；公司董事会于 2025 ...

证券代码：002688 证券简称：金河生物 公 告编号：2025-042 一、股东股份解除质押基本情况 | | 是否为控股股东 | | 本次解除 | | 占其所 | | | 占公司 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 质押开始 | | | | | 质押解除 | | 日 | | | | | | | | | | | | | | 股东名称 | 或第一大股东及 | | 质押股份 | | | 持股份 | | | 总股 | | | | | 本 | | | 质权人 | | | | | | | | | | | | | | | | | | 日期 | | | | | 期 | | | 其一致行动人 | | 数量 | | 比例 | | 比例 | | | | | | | 金河控股 | 是 | | 22,800,000 | | 9.43% | | 2.95% | | | | | | | | | | | | | | 月 30 | | 日 | | 21 | | | 日 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-042 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份解除质押。具体事项如下： 一、股东股份解除质押基本情况 | 股东名称 | 是否为控股股东 | 本次解除 | 占其所 | 占公司 | 质押开始 | | 质押解除日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 或第一大股东及 | 质押股份 | 持股份 | 总股本 | 日期 | | 期 | | | | 其一致行动人 | 数量 | 比例 | 比例 | | | | | | 金河控股 | 是 | 22,800,000 | 9.43% | 2.95% | 2023 年 10 | 2025 | 年 5 月 | 广发证券股 | | | | | | | 月 30 日 | 21 | 日 | 份有限公司 | | 合计 | — | 22,800,000 | 9.43% | 2.95% | — | | — | — | 1、本 ...

Core Viewpoint - Jinhe Biological (002688) announced the release of 22.8 million pledged shares by its controlling shareholder, Jinhe Holdings, which represents 9.43% of its holdings and 2.95% of the company's total share capital [1] Group 1 - The pledged shares were initially pledged on October 30, 2023, and the release date is set for May 21, 2025 [1] - The pledgee for these shares is GF Securities Co., Ltd [1] - As of the announcement date, Jinhe Holdings and its concerted parties have a total of 140 million pledged shares, accounting for 50.31% of their holdings, indicating no risk of forced liquidation [1]

Group 1 - The sugar substitute concept is experiencing a decline in the afternoon trading session, with Baolingbao (002286) nearing a trading halt [1] - Other companies in the sector, including Sanyuan Bio (301206), Jinhai Bio (002688), Vinegar Chemical (603968), and Xinghuo Technology (600866), are also seeing a drop in stock prices [1] - There is an influx of dark pool funds entering these stocks, indicating potential interest from institutional investors [1]

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

Group 1 - The controlling shareholder, Inner Mongolia Jinhai Holdings Co., Ltd., plans to reduce its stake in Jinhai Biological by up to 22,563,389 shares, representing no more than 3% of the total share capital [1] - The reduction will occur within three months from June 10, 2025, to September 9, 2025, through centralized bidding and block trading [1] - The reason for the share reduction is to repay pledged debts, with shares originating from a previous restructuring and capital increases [1] Group 2 - In a previous non-public offering on August 10, 2021, Jinhai Biological issued 145,132,743 shares at a price of 5.65 yuan per share, raising approximately 820 million yuan [2] - After deducting issuance costs, the net funds raised amounted to approximately 802 million yuan, with 145 million yuan allocated to share capital and over 657 million yuan to capital reserves [2]